医学
减肥
荟萃分析
安慰剂
赛马鲁肽
腰围
内科学
临床试验
肥胖
糖尿病
2型糖尿病
替代医学
利拉鲁肽
内分泌学
病理
作者
Di Wang,Houze Diao,Wenhui Sun,Wenru Huan,Yating Wang,Liyi Ding,Weiwei Cui,Ke Ma
摘要
This study found that six FDA-approved weight-loss drugs had a moderately beneficial effect on the cardiometabolic risk profile. In general, tirzepatide was more effective than other pharmacological agents in improving cardiometabolic risk factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI